Tirzepatide

Generic Name
Tirzepatide
Brand Names
Mounjaro
Drug Type
Biotech
Chemical Formula
-
CAS Number
2023788-19-2
Unique Ingredient Identifier
OYN3CCI6QE
Background

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety. Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing. Tirzepatide was approved by the FDA on May 13, 2022, for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. On September 15, 2022, tirzepatide was also approved by the European Commission.

Indication

Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.

This drug has not been studied in patients with a history of pancreatitis. Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News
biospace.com
·

Amylin Commands Weight-Loss Attention as Industry Anticipates Novo's Phase III

Novo Nordisk's CagriSema, combining semaglutide with cagrilintide, could be a breakthrough in obesity treatment. Analysts highlight amylin's role in satiety and hedonic eating, potentially improving weight reduction quality. Phase II results showed a 15.6% weight drop with CagriSema, and Phase III trials are ongoing. Competitors like Lilly and Zealand Pharma also advance amylin-based therapies, with promising early results.

Related Clinical Trials:

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
A Study of LY3841136 in Overweight and Obese Participants
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants
statnews.com
·

We're reading about menopause treatment, Novo plans for Wegovy

Hormone therapy use for menopausal women's heart health has dropped significantly, but new research shows benefits. Novo Nordisk's India team pushes for an early launch of weight loss drug Wegovy to compete with Eli Lilly.
gurufocus.com
·

Novo Nordisk Aims to Fast-Track Wegovy Launch in India to Compete with Eli Lilly

Novo Nordisk accelerates Wegovy launch in India to 2025, aligning with Eli Lilly's Mounjaro. Both drugs are GLP-1 receptor agonists aiding weight loss. India's large population and rising obesity create a significant market, but faces competition from local generic drug manufacturers.
m.economictimes.com
·

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms

Novo Nordisk's India team pushes for an earlier launch of Wegovy, fearing to fall behind Eli Lilly in the weight-loss market. Novo plans to introduce Wegovy in India in 2026, but the India team proposed a 2024 launch. Novo received regulatory approval for injectable semaglutide in India in late 2022.
npr.org
·

Dizzy after one drink? Social drinkers on obesity drugs lose the taste for alcohol

A study finds that moderate drinkers taking obesity drugs like Mounjaro report reduced alcohol consumption, with about 50% cutting back. The study, published in JAMA Network Open, involved 14,000 Weight Watchers members, with those losing more weight more likely to decrease drinking. Researchers suggest the drugs' impact on the brain's reward system may explain the reduction in alcohol use.
crossroadstoday.com
·

Some people don't lose weight with blockbuster obesity drugs

Danielle Griffin, despite easy access to weight loss drugs like Wegovy, found they didn't work for her, losing only 13 pounds in a year and a half. Experts estimate that up to 20% of patients may not respond well to these medications, influenced by factors like genetics, hormones, and medical conditions. Alternative drugs or lifestyle changes may be necessary for effective weight management.
hmri.org.au
·

Mounjaro vs Ozempic: Are they the same?

Mounjaro, a new weight loss drug, is more effective than Ozempic and Wegovy due to dual action on GLP-1 and GIP receptors. It can be prescribed for those with a BMI above 27kg/m2 and weight-related conditions or a BMI over 30kg/m2 alone, but is not yet on PBS, costing $345-$645/month. Side effects include nausea, vomiting, diarrhea, and constipation, with potential for malnutrition. Weight loss effects cease upon drug cessation, emphasizing the importance of a healthy lifestyle for long-term management.
studyfinds.org
·

Medical breakthrough or temporary fix? The brutal truth about weight loss medications

GLP-1 drugs like Ozempic and Mounjaro do not maintain weight loss after discontinuation, with weight regain observed in clinical trials. Chronic treatment is necessary for obesity, similar to other chronic diseases. Strategies to prevent weight regain, such as weaning off the medication, have not been proven effective. Long-term drug usage poses challenges including side effects and lifestyle adjustments, while abrupt cessation can lead to mental health issues. Individualized discussions and creative solutions are essential for long-term weight management.
tradingview.com
·

3 Mega-Cap Stocks to Buy Before They're Worth $1 Trillion

Amazon, Microsoft, Nvidia, Apple, Tesla, and Berkshire Hathaway are trillion-dollar market cap companies. JPMorgan Chase, Walmart, and Eli Lilly are contenders for joining this elite club, with strong financials and growth prospects.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy